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Introduction
Linezolid is a commonly used antibiotic for difficult-to-
treat Gram-positive infections for which little data is
available to guide dosing for different types of renal
replacement therapy.
Objectives
The objective of this study was to compare the popula-
tion pharmacokinetics of linezolid during continuous
venovenous haemofiltration (CVVHF, 30 mL.kg-1.h-1)
and continuous venovenous haemodiafiltration
(CVVHDF, 15 mL.kg-1.h-1 + 15 mL.kg-1.h-1). We then
sought to perform Monte Carlo dosing simulations to
determine doses that best achieve pharmacodynamic
targets for these patients.
Methods
Patients with a clinical indication for linezolid and pre-
scribed either CVVHF or CVVHDF were eligible for par-
ticipation in this prospective pharmacokinetic study.
Patients were administered 600 mg IV 12-hourly. Seven
blood samples were collected over one dosing interval
and analysed by a validated chromatographic method.
Population pharmacokinetic analysis was undertaken
using Pmetrics and Monte Carlo simulations evaluated
achievement of a pharmacodynamics target of an area
under the concentration-time curve from 0-24 hours to
minimum inhibitory concentration (AUC0-24/MIC) of 80.
Results
9 CVVHDF and 8 CVVHF were performed in 13
patients. Patient characteristics regimens of CVVHDF
and CVVHF were similar. A two compartment linear
model best described the data. CVVHDF was associated
with a 20.5% higher mean linezolid clearance than
CVVHF, without statistical significance (P = 0.39). Both
increasing patient weight and decreasing SOFA score
were associated with increasing linezolid clearance. The
mean (SD) parameter estimates were clearance 3.8 (2.2)
L/h, volume of the central compartment 26.5 (10.3) L,
intercompartmental clearance constants from central to
peripheral (Kcp) 8.1 (12.1) L/h and peripheral to central
compartments (Kpc) 3.6 (4.0) L.h-1. Achievement of
pharmacodynamics targets was low for a MIC of 2 mg/L
with the studied dose.
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Figure 1 The median observed linezolid concentration-time p.
Roger et al. Intensive Care Medicine Experimental 2015, 3(Suppl 1):A631
http://www.icm-experimental.com/content/3/S1/A631
© 2015 Roger et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://
creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the
original work is properly cited.
Conclusions
The present data indicates profound pharmacokinetic
variability of linezolid during CVVHF and CVVHDF.
Sub-optimal achievement of therapeutic targets occurs at
the EUCAST breakpoint MIC of 2 mg/L using 600 mg
IV 12-hourly.
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